Vertex Pharmaceuticals reports $12 billion revenue for fiscal year ended December 31, 2025, up 8.9%
Vertex Pharmaceuticals reported revenue of $12 billion for the year ended December 31, 2025, an increase of 8.9% from the previous year ($11.02 billion).
For the same period it posted net income of $3.95 billion, or $15.32 per diluted share (-2.08 a year earlier).
That is a net margin of 32.9%.
On Sanad's AAOIFI Standard 21 screen, Vertex Pharmaceuticals is currently compliant: interest-bearing debt is 3.3% of market capitalisation (limit 30%), and impure income is 4.1% of revenue (limit 5%).
Is Vertex Pharmaceuticals halal?
See the full AAOIFI screening of Vertex Pharmaceuticals
See the full AAOIFI screening of Vertex Pharmaceuticals
Source: 10-K filed with the U.S. Securities and Exchange Commission on February 13, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.